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Chemokines are important mediators of the immune response to pathogens, but can also
promote chronic inflammatory states. Chemokine receptor 6 (CCR6) is found on immature
DC and effector/memory T cells, and binds a single ligand, CCL20, with high affinity. Here,
we investigated the role of CCL20 and CCR6 in a pulmonary viral infection caused by RSV,
a ubiquitous virus that can cause severe pulmonary complications. Neutralization of
CCL20 during RSV infection significantly reduced lung pathology and favored a Th1
effector response. CCR6-deficient animals recapitulated this phenotype, and additionally
showed enhanced viral clearance when compared with WT mice. No differences were
observed in migration of T cells to the lungs of CCR6/ animals; however, a significant
reduction was observed in numbers of conventional DC (cDC), but not plasmacytoid DC, in
CCR6/ mice. A pathogenic phenotype could be reconstituted in CCR6/ mice by
supplying cDC into the airway, indicating that mere number of cDC dictates the adverse
response. Our data suggest that blockade of the CCL20/CCR6 pathway provides an
environment whereby the attenuated recruitment of cDC alters the balance of innate
immune cells and mediates the efficient antiviral response to RSV.
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Introduction
RSV is a pervasive virus that is the most common cause of
hospitalization in children under the age of 2 [1]. RSV can also
adversely affect the elderly and immunocompromised individuals,
causing severe lower respiratory tract infection [2]. Although both
Th1 and Th2 effector responses may be generated, Th2 immunity
is responsible for RSV-associated pathology, including airway
damage and mucus hypersecretion [3]. RSV represents a recurrent
problem throughout life because immunologic memory never fully
develops [4]. Furthermore, studies have demonstrated a correla-
tion between early exposure to RSV and the later development of
asthma [5, 6]. No vaccine currently exists, and early attempts to
develop a vaccine proved detrimental, as individuals inoculated
with a formalin-inactivated form of virus demonstrated enhanced
pulmonary eosinophilia and Th2 responses [7]. Clearly, further
investigation is needed to clarify the fine balance between immune
protection and pathology during RSV infection.
Chemokines are key mediators of leukocyte recruitment
during pathogenic insult, and also play a prominent role in
homeostasis [8]. Most chemokines are promiscuous in that they
can bind multiple receptors. CC chemokine receptor 6 (CCR6) is
unique in the latter regard in that it binds a single chemokine,
CCL20 [9]. CCL20 is a homeostatic chemokine, with a prominent
role in organizing lymphoid tissue in the gut [10], but is also
upregulated upon pro-inflammatory stimulation [11]. This dual
function of CCL20 is evident in the cells expressing its
corresponding receptor, CCR6, and contributes to a role for these
cells in various immune settings.
CCR6 is found on immature DC, B cells, effector/memory T cells
and T regulatory cells [12–15]. Studies have identified CCR6 as
contributing to the pathology of inflammatory conditions such as
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asthma [16], autoimmune disorders such as rheumatoid arthritis
[17] and graft versus host disease [18]. However, studies examin-
ing the effect of CCR6 deficiency on pathogen clearance showed
defective DC recruitment, resulting in reduced T-cell-mediated
control of infection [19, 20]. Thus, CCR6 contributes to both
immune pathogenesis and appropriate immunity to pathogens.
Herein, we investigated the impact of CCR6 deficiency on
appropriate immunity to RSV, and the contribution of DC and
T cells to the response. We used a blocking Ab to CCL20 in
conjunction with CCR6-deficient mice to show that RSV-induced
pathology was attenuated in these animals, and a predominant Th1
effector response was generated. CCR6/ mice had a significant
decrease in conventional DC (cDC) in the lungs, however, plasma-
cytoid DC (pDC), which have been demonstrated to limit viral
replication and modulate immunopathology following RSV infec-
tion [21, 22], were recruited equally. Several studies have eluci-
dated the differential roles played by cDC and pDC in the lung, and
suggest a critical balance between these DC subsets in order for
appropriate responses to occur to both innocuous and pathogenic
stimuli [21, 23]. Our data support this concept, suggesting that
appropriate immunity to RSV involves an altered balance of DC
subsets, where reduced recruitment of cDC promotes a beneficial
Th1-based environment.
Results
Treatment with anti-CCL20 alters the immune
response to RSV infection
Previous studies demonstrated a pathological role for CCR6 in
mouse models of disease [16, 24, 25]. To determine whether
CCR6/CCL20 played a role during RSV-induced disease, we
infected mice intratracheally with 5 104 PFU RSV and assayed
for production of CCL20 in BALF. We found increased levels of
CCL20 at days 1 and 2 post-RSV challenge (Fig. 1A), indicating
Figure 1. Anti-CCL20-treated mice have reduced lung pathology and lower Th2 cytokines. Mice were infected with 5104 PFU of RSV/mouse via
intratracheal injection. Lungs and lymph nodes were harvested at day 6 post-infection for analysis. (A) Protein levels of CCL20 were determined by
ELISA in BALF of BALB/c mice after RSV infection. Data show mean7SE from five mice/timepoint. (B) Schematic of anti-CCL20 Ab administration to
BALB/c mice. (C) Histology of mucus production in Ab-treated mice. Data are representative of samples from four mice/group, magnified 100. (D)
Expression of Muc5ac and Gob5 was assessed in lung samples by RT-PCR. Data are expressed as fold increase over uninfected mice and show
mean1SE from five mice/group. po0.05. (E) RSV-specific T-cell cytokines were determined by Bioplex in lymph node cultures restimulated with
RSV. Data show mean1SE from five mice/group. po0.05. All data shown are representative of two independent experiments.
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that CCL20 is important in mediating leukocyte recruitment early
upon infection with RSV.
To determine whether CCL20 had a pathogenic role, BALB/c
mice were treated with a neutralizing Ab to CCL20 prior to and
during infection with RSV (Fig. 1B). Histological examination of
lungs revealed a decrease in mucus production in mice treated
with anti-CCL20 (Fig. 1C). Consistent with this, anti-CCL20-
treated mice had significantly reduced expression of the mucus-
associated genes, Muc5ac and Gob5 (Fig. 1D). RSV-specific T-cell
responses were next assessed by restimulating lymph node
cultures with RSV. Mice treated with anti-CCL20 exhibited
reduced expression of the Th2 cytokines, IL-4 and IL-13, but
showed no difference from control-treated mice in the Th1
cytokine, IFN-g (Fig. 1E). Together, these studies indicate that
CCR6-CCL20 plays a pathological role during RSV infection, and
influences the nature of the T-cell response.
Differential expression of CCR6 on leukocytes during
RSV infection
To investigate the contribution of leukocytes during RSV infection,
the expression pattern of CCR6 on subsets of DC and T cells was
examined in the lung by flow cytometry. A significant increase was
seen in numbers of CCR61 MHC II1 CD11b1 CD11c1cDC on day 2
following RSV infection (Fig. 2A). An insignificant increase was
seen in CCR61 CD11c1 B2201pDC (Fig. 2B). When T-cell subsets
were assessed, a significant increase was found in numbers of
CCR61 CD691(activated) CD41 T cells at day 6 post-infection
Figure 2. CCR61 cDC and CCR61 CD4 T cells are increased in lung after RSV infection. Mice were infected with 5 104 PFU of RSV/mouse via
intratracheal injection. Lungs were harvested at day 6 post-infection for analysis. (A) CCR61 cDC were assessed in lung tissue by flow cytometry.
Autofluorescence was gated out and cells were gated on the CD11b1CD11c1 population and analyzed for MHC class II and CCR6 expression. Graph
shows total numbers of cDC in each sample and represents the mean1SE from five mice/group. po0.05. (B) CCR61 pDC were assessed in lung
tissue by flow cytometry. Samples were gated on the lymphocyte cell population and the CD11cint population was analyzed for CCR6 and B220
expression. Graph shows total numbers of pDC in each sample and represents the mean1SE from five mice/group. (C) CCR61CD691 CD41 T cells
were assessed in lung tissue by flow cytometry. Samples were gated on the lymphocyte population and the CD41 population was analyzed for
CCR6 and CD69 expression. Graph shows total numbers of T cells in each sample and represents the mean1SE from five mice/group. po0.05. All
data shown are representative of two independent experiments.
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(Fig. 2C), but not CCR61 CD691 CD81 T cells (data not shown).
These data indicate that CCR6-expressing cDC and CD4 T cells are
increased in the lung after RSV infection, and thus may play a role
in the anti-viral immune response.
CCR6/ mice display reduced pathology but control
RSV more efficiently
To assess the mechanism and specific cells involved in the altered
pathogenic phenotype seen in mice treated with anti-CCL20,
mice deficient in CCR6 were used in our RSV model. Like anti-
CCL20-treated mice, CCR6/ mice demonstrated reduced
mucus production in the lungs, as shown histologically
(Fig. 3A), and by significantly lower expression of Gob5
(Fig. 3B). CCR6/mice also exhibited significantly lower airway
resistance compared with WT mice (Fig. 3C).
To determine whether the decreased pathology observed in
CCR6/ animals affected their ability to control infection with
RSV, whole lungs were isolated at day 3 to determine viral titer.
CCR6/ mice had significantly fewer plaques than WT mice,
suggesting that CCR6/ animals were better able to control viral
replication (Fig. 3D). To insure that both strains were infected
equally, transcript levels of the RSV G protein were measured by
RT-PCR, with no differences found at either day 1 or day 2 post-
infection (Fig. 3E). Because CCR6/ animals had more efficient
handling of RSV, we examined early recruitment of NK cells,
which have been shown to participate in RSV clearance prior to
T-cell involvement [26]. Paradoxically, a 50% reduction in NK
cells was seen in CCR6/ mice at day 2, suggesting that other
innate cells are involved in the early anti-viral response to RSV in
these animals (data not shown). Thus, CCR6/ mice appear to
have a decreased pathological response to RSV coincident with
more efficient viral clearance.
Altered T-lymphocyte response in CCR6/ mice
To examine the T-cell phenotype in CCR6/ animals after RSV
infection, migration of CD691 CD4 T cells into the lungs was
assessed by flow cytometry. No differences were seen between
WT and CCR6/ mice in numbers of activated CD41 T cells at
days 6 or 8 (Fig. 4A). We also assayed for this subset of T cells in
the lymph nodes and likewise found no differences between the
groups (data not shown).
RSV-specific effector T-cell responses were next assessed by
lymph node restimulation with RSV. CCR6/ mice produced
significantly less IL-4 and IL-13, but exhibited no difference from
WT mice in IFN-g production (Fig. 4B, left panel). In support of this
data, lymph node cells stimulated with anti-CD3/anti-CD28 also
demonstrated Th2 skewing by WT animals (Fig. 4B, right panel).
Recent work has identified CCR6 to be a primary receptor on Th17
cells [15]. In our model, we found RSV-specific induction of IL-17,
but no difference in this induction, or in the recruitment of Th17
cells, by CCR6/ mice (data not shown). This is not surprising, as
studies have shown that Th17 development is inhibited by Type I
IFN [27, 28]; furthermore, Hashimoto et al. found augmented IL-17
in mice deficient for STAT1, the transcription factor responsible for
IFN-a/b expression, after infection with RSV [29]. Thus, IL-17 does
not appear to play a role in influencing the phenotype of CCR6/
animals after RSV infection.
Effector cytokine expression was then examined in the lungs
of WT and CCR6/ mice by RT-PCR. Similar to the response
generated in the lymph node, CCR6/ mice expressed signifi-
cantly lower levels of IL-4 and IL-13 (Fig. 4C). However, reduced
expression of IFN-g was also seen in CCR6/ mice (Fig. 4C). As
we saw similar numbers of CD691 CD4 T cells in the lungs of WT
Figure 3. CCR6/ mice have reduced lung pathology and more
efficient viral clearance. Mice were infected with 5 104 PFU of RSV/
mouse via intratracheal injection. Lungs were harvested at days 1, 2
and 3 to assess viral transcript levels and titer, and at days 6, 8 and
9 for analysis of mucus and airway hyperreactivity. (A) Mucus
production in the lung was assessed in CCR6/ mice by histology.
Data are representative of samples from four mice/group, magnified
200 . (B) Gob5 gene expression was assessed in lung samples by
RT-PCR. Data are expressed as fold increase over uninfected mice and
represent the mean1SE from four mice/group/experiment; data are
pooled from two experiments. po0.05. D6 and D8 represent days 6 and
8 post-infection, respectively. (C) Airway hyperreactivity was deter-
mined using whole body plethysmography. Data represent the
mean7SE from four mice/group. po0.05. D6 and D8 represent days 6
and 8 post-infection, respectively. (D) RSV viral titer was determined by
plaque assay at day 3 post-infection. Data represent the mean1SE
from five mice/group. po0.05. (E) RSV protein G transcript levels were
measured in lung samples by RT-PCR. Data are expressed as fold
increase over WT-challenged mice on day 1, and represent the
mean7SE from four mice/group. All data shown are representative
of three independent experiments.
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and CCR6/ animals, we examined the intracellular cytokine
profile of lung CD4 T cells. Consistent with the expression data,
CCR6/ animals displayed reduced numbers of IL-41 and
IFN-g1 CD4 T cells in the lung (Fig. 4D). Intracellular cytokine
staining in the lymph node likewise reflected our Bioplex data,
with CCR6/ animals showing reduced numbers of IL-41 CD4 T
cells but similar numbers of IFN-g1 CD4 T cells compared with
WT animals (data not shown). Together, these data indicate that
after infection with RSV, CCR6/ mice exhibit an altered Th
cytokine phenotype in lungs and lymph nodes, with a less
pathogenic profile of cytokines in the lung.
To further examine the cytokine milieu, BALF was collected
early after RSV infection and chemokines associated with a Th1
immune environment were assessed [30]. Significantly, higher
production of CXCL10 and CCL5 was found in the BALF of
CCR6/ mice; CXCL9, which binds the same receptor as
CXCL10, was also elevated, but was not significantly different in
CCR6/ mice (Fig. 4E). Thus, the early milieu in CCR6/
animals may influence the subsequent response by providing a
more favorable environment for activation of appropriate subsets
of effector cells.
cDC promote Th2 pathology upon RSV infection
Because CCR6/ animals cleared virus more efficiently and
showed an overall decrease in Th effector cytokine production in
the lung, we hypothesized that innate cells, such as macrophages
and DC, were influencing the early antiviral response to RSV.
Macrophage recruitment was first assessed by flow cytometry,
with no difference found between the strains in macrophage
numbers (data not shown). Interestingly, a recent study demon-
strated that macrophage depletion had no effect on T-cell
responses to RSV infection [31]. DC, on the other hand, both
participate in activating RSV-specific T cells (cDC) [32], as well as
promote direct anti-viral immunity through production of IFN-a
(pDC) upon RSV stimulation [33]. When cDC and pDC subsets
were assessed, CCR6/ mice had significantly fewer cDC
recruited into the lungs at day 2 post-infection (Fig. 5A).
However, no difference was found in numbers of pDC
(Fig. 5B). Consistent with the latter data, no difference was
found in the production of IFN-a in whole lung and BALF of WT
and CCR6/ mice (data not shown). To further confirm that the
defective trafficking of cDC in CCR6/ animals was due to the
Figure 4. CCR6/ mice have an altered T-cell response following RSV infection. Mice were infected with 5 104 PFU of RSV/mouse via
intratracheal injection. Lungs were harvested at days 6 and 8 to assess T-cell recruitment, and both lungs and lymph nodes were harvested at day 6
for cytokine analysis. (A) Recruitment of CD691 CD41 T cells to the lungs was determined by flow cytometry. Data represent the mean7SE from
four mice/group. (B) RSV-specific T-cell cytokines were assessed by Bioplex in lymph node cultures at day 6 post-RSV infection. Left panel: lymph
node cultures restimulated with RSV. Data represent the mean1SE from four mice/group. po0.05. Right panel: lymph node cultures restimulated
with anti-CD3/anti-CD28. Data represent the mean1SE from five mice/group. po0.05. (C) Cytokine gene expression was determined by RT-PCR in
lung samples at day 6 post-RSV infection. IL-13 and IFN-g are expressed as fold increase over WT-challenged samples, and IL-4 expressed as fold
increase over unchallenged samples. IL-4 and IL-13 data represent the mean1SE from four mice/group; IFN-g data represent the mean1SE from
four mice/group/experiment, data are pooled from three experiments. po0.05. (D) Intracellular cytokine staining was assessed by flow cytometry
in lung samples at day 6 post-RSV infection. Total IL-41 CD41 and IFN-g1 CD41 cells are shown. Data represent the mean1SE from five mice/group.
po0.05. (E) Th1-associated chemokines were assessed by Bioplex in BALF. Data represent the mean1SE from four mice/group. po0.05. Data shown
in (A–C) are representative of three independent experiments; data in (D) and (E) are representative of two independent experiments.
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absence of CCR6, we assayed for CCR61 cDC in animals treated
with anti-CCL20 and infected with RSV. We found significantly
reduced numbers of CCR61 cDC in mice that were administered
anti-CCL20 (Fig. 5C). Together with our T-cell data, these studies
suggest that the absence of early recruitment of cDC alters the
immune response to RSV in CCR6/ animals, potentially by
abrogating the Th2 response while maintaining effective IFN-g
production.
To test whether cDC administration to CCR6/ animals
could recapitulate the lung pathology and Th2-biased responses
seen in WT mice, 5105 WT BMDC were transferred intra-
tracheally [34–36] into CCR6/ animals immediately prior to
intranasal administration of RSV. Upon histological analysis,
CCR6/ mice receiving either WT or CCR6/ cDC had
increased mucus production compared with CCR6/ mice not
receiving cDC (Fig. 5D). Measurement of Muc5ac and Gob5
gene expression supports the histology (Fig. 5E). When RSV-
specific cytokine responses were assessed, CCR6/ mice
receiving either WT or CCR6/ cDC produced elevated levels
of IL-4 and IL-13, but showed no difference in IFN-g
compared with CCR6/ mice not receiving cDC (Fig. 5F). While
the Th2 cytokine responses were not statistically significant,
the trends along with the pathology suggest that merely supply-
ing additional cDC, regardless of CCR6 expression, partially
reconstitutes the response. This supports a role for cDC in
promoting the Th2-biased pathology after RSV infection in WT
mice, and that CCR6 mediates the recruitment of this subset of
DC into the lung.
CCR6/ cDC have competent antigen presenting
function
The above data demonstrates that CCR6/ cDC are capable
of priming a Th2 response when transferred into the lungs of
CCR6/ animals. To further confirm the functional capacity
of CCR6/ cDC in vitro, cDC ability to restimulate a primed
RSV T-cell response was examined. BM-derived cDC were
stimulated with RSV and co-cultured with CD41 T cells isolated
from lymph nodes of WT and CCR6/ mice at day 8 post-RSV
infection. In agreement with our lymph node restimulation data,
CCR6/ T cells were skewed toward a Th1 phenotype,
irrespective of origin of DC in the culture (Fig. 6A). Thus,
CCR6/ cDC are capable of antigen presentation to the same
extent as WT cDC.
Next, cDC contribution to a primary T-cell response was
examined using DO11.10 mice. cDC were pulsed with OVA
peptide and co-cultured with CD41 T cells isolated from the
spleens of DO11.10 mice. Upon analysis of cytokine production,
CCR6/ cDC were equally able to elicit Th1 and Th2 cytokine
production from OVA-specific T cells (Fig. 6B). Together, these
studies suggest that cDC from CCR6/ animals are capable of
priming both Th1 and Th2 responses, but upon RSV infection,
CCR6/ cDC are skewed by their in vivo environment, allowing
them to preferably prime a Th1 response.
Discussion
This study investigated the role of CCR6 and its ligand, CCL20, in
a model of pulmonary viral infection induced by RSV. Previous
studies demonstrated this receptor to be essential for pathogen
clearance in the gut, such as in models using Salmonella
typhimurium [19] and murine enteric rotavirus [37], as well as
in the lung, using Aspergillus fumigatus [38]. However, CCR6 has
also been implicated in the pathology of diseases such as asthma,
inflammatory bowel disease and psoriasis [39–41]. In our studies,
mice treated with an Ab to CCL20 and infected with RSV
exhibited significantly decreased mucus production in the lung
and generated a T-cell response favoring IFN-g-production.
Further investigation using CCR6/ mice showed that these
animals likewise had attenuated RSV-induced pathology and a
predominant Th1 effector response when compared with WT
mice. Examination of leukocyte trafficking to the lungs of
CCR6/ animals revealed no differences in T-cell accumulation,
but significant decreases in early cDC recruitment. Effector T-cell
cytokines were reduced in CCR6/ animals; however, viral
clearance was enhanced. Together, these data suggest that the
early pulmonary environment, characterized by a reduction in
cDC recruitment, is key in shaping the subsequent immune
response to RSV by CCR6/ mice.
Several recent studies have demonstrated the importance of
pulmonary DC in mediating the immune response to RSV.
Different subsets of cDC, including CD1031 and CD103 popu-
lations, migrate to the lymph nodes and activate RSV-specific
CD4 and CD8 T cells [32], while pDC mobilize directly to mucosal
tissue upon RSV infection [32, 42]. Interestingly, RSV has been
shown to interfere with cDC and pDC function, resulting in
reduced cytokine production and impaired T-cell activation
[43, 44]. In the latter study, T-cell activation was assessed using
proliferation assays, whereas our studies examined RSV-specific
effector cytokine production. It is likely that these pathways are
differently regulated and therefore account for the differences
seen in T-cell activation. The DC studies suggest that subversion
of DC function may impact on the inadequate long-term immu-
nity to RSV infection. Thus, DC clearly play a part in shaping the
anti-viral response.
To further investigate the role of DC during RSV infection, we
infected mice that were deficient in the mucosa-specific
chemokine receptor, CCR6, which mediates cDC migration to the
lung upon inflammatory stimuli [45]. When stimulated with RSV,
cDC become activated and upregulate the costimulatory mole-
cules CD40, CD80 and CD86, and when pulsed with OVA and
RSV, prime OVA-specific Th1 and Th2 responses [33]. In our
studies, CCR6/ cDC were defective in their ability to traffic to
the lung, but were not deficient in their capacity to prime either
Th1 or Th2 responses using an in vitro co-culture assay with OVA-
specific T cells. In vivo, however, CCR6/ mice generated a
predominant Th1 response, and reconstitution of these mice with
either WT or CCR6/ cDC reverted the phenotype to the mixed
Th1/Th2 response, and enhanced lung pathology, seen in WT
mice. These latter data indicate that the alteration observed in the
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CCR6/ mice is related to the number of cDC migrating to the
lung early in the response.
Alternatively, we found no defect in accumulation of pDC in
the lungs of CCR6/ mice after RSV infection, and this differ-
ence in migratory behavior between cDC and pDC highlights the
distinct role these DC subsets play in the lung. For example,
cDC activated in the lung have been shown to preferentially
induce Th2 effector responses [46], and only under particular
stimulatory conditions will induce a Th1 response, such as upon
exposure to Type I IFN [47]. pDC, on the other hand, produce
IFN-a upon stimulation with RSV [33], and this Type I environ-
ment likely influences the activational state of cDC. The influence
of pDC during RSV infection has been verified by both depletion
[21] and repletion [22] protocols, and demonstrates a beneficial
role for pDC on viral clearance and lung pathology. Together with
the current data, it is our view that the balance between pDC and
Figure 5. CCR6/mice have reduced cDC recruitment, and reconstitution of animals with cDC promotes Th2 pathology. (A) Lung cDC recruitment
was assessed by flow cytometry in WT and CCR6/ mice. Lung cells were gated on CD11b and CD11c expression and analyzed for MHC class II
expression. Graph shows mean number of cDC1SE from four mice/group. po0.05. (B) Lung pDC recruitment was assessed by flow cytometry in the
same mice as (A) gating on CD11c1B2201 cells. Data represent the mean1SE from four mice/group. (C) CCR61 cDC recruitment was assessed by
flow cytometry in RSV-infected animals treated with anti-CCL20. Data represent the mean1SE from five mice/group. po0.05. (D) Mucus production
was assessed by histology in WT and CCR6/ animals reconstituted with cDC. Shown are representative samples from five mice/group, magnified
400 . (E) Mucus-associated gene expression was determined in DC transfer groups by RT-PCR, and represented as fold increase over unchallenged
samples. x-axis indicates recipient animals; cDC transferred are indicated below the x-axis. Data represent the mean1SE from five mice/group.
po0.05. (F) RSV-specific T-cell cytokines were measured by Bioplex in lymph node cultures of DC transfer groups. Data represent the mean1SE
from five mice/group/experiment; data are pooled from three experiments. Data shown in (A) and (D–F) are representative of three independent
experiments; data in (B) and (C) are representative of two independent experiments.
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cDC is critical for RSV clearance and the nature of the subsequent
T-cell response.
In support of cDC promoting a pathogenic response are
numerous studies demonstrating that they alone induce a skew
toward Th2-associated disease. An original study that isolated
cDC subsets indicated that the response to allergen was skewed
toward a Th2 response exclusively by a subset of lung DC [48].
Subsequently, cDC have been classified into DC1 and DC2 subsets
based on their ability to activate T cells into Th1 and Th2
effectors, respectively [49, 50]. Although this study has not
characterized these subsets, it appears that CCR6 influences the
recruitment of cDC in general and it may be the mucosal
environment that dictates the ability of cDC to promote a
pathogenic Th2 response. The nature of the response and envir-
onment can be influenced by specific mediators, including
epithelial cell-derived thymic stromal lymphopoietin, which
promotes the upregulation of OX40 on cDC and skews T cells
toward a Th2 phenotype [51]. Other mediators, such as CXCL9,
CXCL10 and CCL5, have been associated with promoting a Th1-
skewed environment [30], and this study shows elevated
production of these chemokines in BALF of CCR6/ mice. Thus,
the early cytokine environment along with the absence of a Th2-
promoting cDC subset may favor generation of a predominant
Th1 response.
Overall, using this infection model, WT mice generated IL-13
and IFN-g Th effector responses to RSV, but in the absence of the
CCL20/CCR6-associated immune pathway, mice instead initiated
an IFN-g-dominated antiviral response. cDC recruitment was
impaired in CCR6/ mice, yet the recruitment and function of
pDC remained intact. When cDC, whether WT or CCR6/, were
provided into the lungs, the more pathogenic Th2 response was
partially reestablished. This suggests a model whereby a cytokine
milieu established by the altered balance of cDC and pDC in
CCR6/ mice favors the generation of a Th1-based, efficient




BALB/c and DO11.10 mice were purchased from Jackson
Laboratories. CCR6/ mice were provided by Dr. Sergio
Lira. All animal work was performed in accordance with the
University of Michigan Committee on Use and Care of Animals
policy.
RSV
Our laboratory uses the antigenic subgroup A strain of RSV,
referred to as Line 19, which induces RSV-associated disease [52].
Figure 6. CCR6/ cDC can prime both Th1 and Th2 T-cell responses. (A) T cells from RSV-challenged mice were co-cultured with RSV-primed
CCR6/ and WT DC to assess the T-cell response as determined by IL-4, IL-13 and IFN-g secretion. Data represent the mean1SE from triplicates/
group. po0.05. (B) OVA-specific, primary T-cell responses as determined by IL-4, IL-13 and IFN-g secretion were measured after co-culture with
OVA-primed CCR6/ and WT DC. Data represent the mean1SE from three replicates/group. po0.05. All data shown are representative of three
independent experiments.
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Ab administration
50 mg per mouse of rat anti-mouse CCL20 Ab, clone 114908 (R&D
Systems, Minneapolis, MN, USA), was administered either
intratracheally at the time of RSV infection, and 1 day after,
until day 2, or intraperitoneally 2 h prior to infection, and every
other day thereafter until day 6.
Histology
Left lobes were removed and perfused with 10% formalin. Tissue
was paraffin-embedded and 5 mm sections were stained with
periodic acid schiff to detect mucus production.
Real-time taqman PCR
Lung RNA was obtained using Trizol reagent per the Invitrogen
protocol. Detection of cytokine mRNA was determined using
predeveloped primer/probe sets (PE Biosystems, Foster City, CA)
and analyzed using the ABI Prism 7500 Sequence Detection
System (Applied Biosystems, Foster City, CA). Gene expression
was normalized to GAPDH.
Flow cytometry
Lung tissue was digested and dispersed to obtain single-cell
suspensions. Cells were Fc-blocked, stained with fluorophore-
conjugated Ab and fixed in 4% formalin. For intracellular
cytokine staining, cells were first stimulated for 6 h with 50 ng/
mL of PMA and 10 mM of ionomycin, with inclusion of protein
transport inhibitor. Analysis was conducted using FlowJo soft-
ware.
RSV-specific T-cell response
Mediastinal and cervical lymph nodes were harvested and single-
cell suspensions obtained. Samples were plated at 1106 cells
per well and restimulated for 24 h with either 4104 PFU RSV or
1mg/mL of anti-CD3 and anti-CD28.
Airway response
Airway hyperreactivity was determined using whole body
plethysmography with ventilation of anesthetized mice as
described previously [52].
Viral plaque assay
Whole lungs were harvested and ground with sand using a mortar
and pestle. Supernatants were serially diluted onto Vero cells and
incubated for 5 days. Viral plaques were determined using a goat
anti-human RSV polyclonal Ab (Chemicon International).
DC transfer
BM was cultured for 10 days in 10 ng/mL of murine GM-CSF
(R&D Systems) to generate DC. Briefly, 5105 DC were
transferred intratracheally.
In vitro co-cultures
BMDC were pulsed for 2 h with either 4 104 PFU RSV or 1mg/
mL of OVA peptide (323–339, Peptides International) and
incubated with CD41 T cells isolated from lymph nodes or spleen
by MACSs cell separation (Miltenyi Biotec).
Statistical analysis
Data were analyzed using Prism GraphPad software. Unless
otherwise specified, data shown are representative of two or
more experiments. Statistical significance in all experiments was
determined by one-way ANOVA followed by a Newman–Keuls
post hoc test. Significant differences were regarded as po0.05.
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